Texas Health and Safety Code
Sec. § 171.063
Distribution of Abortion-inducing Drug


(a)

A person may not knowingly give, sell, dispense, administer, provide, or prescribe an abortion-inducing drug to a pregnant woman for the purpose of inducing an abortion in the pregnant woman or enabling another person to induce an abortion in the pregnant woman unless:

(1)

the person who gives, sells, dispenses, administers, provides, or prescribes the abortion-inducing drug is a physician; and

(2)

except as otherwise provided by Subsection (b), the provision, prescription, or administration of the abortion-inducing drug satisfies the protocol tested and authorized by the United States Food and Drug Administration as outlined in the final printed label of the abortion-inducing drug.

(b)

A person may provide, prescribe, or administer the abortion-inducing drug in the dosage amount prescribed by the clinical management guidelines defined by the American Congress of Obstetricians and Gynecologists Practice Bulletin as those guidelines existed on January 1, 2013.

(c)

Before the physician gives, sells, dispenses, administers, provides, or prescribes an abortion-inducing drug, the physician must examine the pregnant woman and document, in the woman’s medical record, the gestational age and intrauterine location of the pregnancy.

(d)

The physician who gives, sells, dispenses, administers, provides, or prescribes an abortion-inducing drug shall provide the pregnant woman with:

(1)

a copy of the final printed label of that abortion-inducing drug; and

(2)

a telephone number by which the pregnant woman may reach the physician, or other health care personnel employed by the physician or by the facility at which the abortion was performed with access to the woman’s relevant medical records, 24 hours a day to request assistance for any complications that arise from the administration or use of the drug or ask health-related questions regarding the administration or use of the drug.

(e)

The physician who gives, sells, dispenses, administers, provides, or prescribes the abortion-inducing drug, or the physician’s agent, must schedule a follow-up visit for the woman to occur not more than 14 days after the administration or use of the drug. At the follow-up visit, the physician must:

(1)

confirm that the pregnancy is completely terminated; and

(2)

assess the degree of bleeding.

(f)

The physician who gives, sells, dispenses, administers, provides, or prescribes the abortion-inducing drug, or the physician’s agent, shall make a reasonable effort to ensure that the woman returns for the scheduled follow-up visit under Subsection (e). The physician or the physician’s agent shall document a brief description of any effort made to comply with this subsection, including the date, time, and name of the person making the effort, in the woman’s medical record.

(g)

If a physician gives, sells, dispenses, administers, provides, or prescribes an abortion-inducing drug to a pregnant woman for the purpose of inducing an abortion as authorized by this section and the physician knows that the woman experiences a serious adverse event, as defined by the MedWatch Reporting System, during or after the administration or use of the drug, the physician shall report the event to the United States Food and Drug Administration through the MedWatch Reporting System not later than the third day after the date the physician learns that the event occurred.
Added by Acts 2013, 83rd Leg., 2nd C.S., Ch. 1, Sec. 3, eff. October 29, 2013.
Source
Last accessed
Sep. 20, 2020